50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,647.29
DOW   29,134.99
QQQ   274.48
Layoffs Aren't the Solution to Your Profitability Crisis. Here's the Simple 4-Step Process You Should Be Following Instead.
CEO of biggest PE firm predicts “social unrest” (Ad)
Is There Value In These Growth Stocks?
Build A Better Tech Portfolio With Jabil Inc.
CEO of biggest PE firm predicts “social unrest” (Ad)
US stocks end mixed a day after Dow entered a bear market
Autodesk Is A Mature Company Still Acting Like A Growth Stock
How To Earn a Tax-Advantaged 10% Dividend Yield (Ad)pixel
Leaks on Russian gas pipelines raise concerns about sabotage
Vote in Ukraine's Russia-held areas stokes tension with West
S&P 500   3,647.29
DOW   29,134.99
QQQ   274.48
Layoffs Aren't the Solution to Your Profitability Crisis. Here's the Simple 4-Step Process You Should Be Following Instead.
CEO of biggest PE firm predicts “social unrest” (Ad)
Is There Value In These Growth Stocks?
Build A Better Tech Portfolio With Jabil Inc.
CEO of biggest PE firm predicts “social unrest” (Ad)
US stocks end mixed a day after Dow entered a bear market
Autodesk Is A Mature Company Still Acting Like A Growth Stock
How To Earn a Tax-Advantaged 10% Dividend Yield (Ad)pixel
Leaks on Russian gas pipelines raise concerns about sabotage
Vote in Ukraine's Russia-held areas stokes tension with West
S&P 500   3,647.29
DOW   29,134.99
QQQ   274.48
Layoffs Aren't the Solution to Your Profitability Crisis. Here's the Simple 4-Step Process You Should Be Following Instead.
CEO of biggest PE firm predicts “social unrest” (Ad)
Is There Value In These Growth Stocks?
Build A Better Tech Portfolio With Jabil Inc.
CEO of biggest PE firm predicts “social unrest” (Ad)
US stocks end mixed a day after Dow entered a bear market
Autodesk Is A Mature Company Still Acting Like A Growth Stock
How To Earn a Tax-Advantaged 10% Dividend Yield (Ad)pixel
Leaks on Russian gas pipelines raise concerns about sabotage
Vote in Ukraine's Russia-held areas stokes tension with West
S&P 500   3,647.29
DOW   29,134.99
QQQ   274.48
Layoffs Aren't the Solution to Your Profitability Crisis. Here's the Simple 4-Step Process You Should Be Following Instead.
CEO of biggest PE firm predicts “social unrest” (Ad)
Is There Value In These Growth Stocks?
Build A Better Tech Portfolio With Jabil Inc.
CEO of biggest PE firm predicts “social unrest” (Ad)
US stocks end mixed a day after Dow entered a bear market
Autodesk Is A Mature Company Still Acting Like A Growth Stock
How To Earn a Tax-Advantaged 10% Dividend Yield (Ad)pixel
Leaks on Russian gas pipelines raise concerns about sabotage
Vote in Ukraine's Russia-held areas stokes tension with West
NASDAQ:BCDA

BioCardia - BCDA Stock Forecast, Price & News

$2.02
+0.04 (+2.02%)
(As of 09/27/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.92
$2.05
50-Day Range
$1.36
$2.09
52-Week Range
$1.10
$3.49
Volume
21,688 shs
Average Volume
719,085 shs
Market Capitalization
$35.87 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.50

BioCardia MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
221.8% Upside
$6.50 Price Target
Short Interest
Healthy
0.71% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.15mentions of BioCardia in the last 14 days
Based on 5 Articles This Week
Insider Trading
Acquiring Shares
$7,898 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.90) to ($0.97) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.36 out of 5 stars

Medical Sector

373rd out of 1,071 stocks

Biological Products, Except Diagnostic Industry

63rd out of 172 stocks

BCDA stock logo

About BioCardia (NASDAQ:BCDA) Stock

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.

Receive BCDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioCardia and its competitors with MarketBeat's FREE daily newsletter.

BCDA Stock News Headlines

Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast
He predicted the 2020 crash a month before it happened…He predicted this year’s collapse back in January… And now, he’s issuing a brand-new warning – along with a unique solution.
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast
He predicted the 2020 crash a month before it happened…He predicted this year’s collapse back in January… And now, he’s issuing a brand-new warning – along with a unique solution.
BioCardia Dives on Heart Trial - Baystreet.ca
Recap: BioCardia Q2 Earnings - Benzinga
BioCardia Earnings Preview - Benzinga
See More Headlines
Receive BCDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioCardia and its competitors with MarketBeat's FREE daily newsletter.

BCDA Company Calendar

Last Earnings
8/10/2022
Today
9/27/2022
Next Earnings (Estimated)
11/09/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BCDA
Employees
28
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.50
High Stock Price Forecast
$9.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+221.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-12,620,000.00
Net Margins
-619.91%
Pretax Margin
-619.75%

Debt

Sales & Book Value

Annual Sales
$1.01 million
Book Value
$0.61 per share

Miscellaneous

Free Float
13,620,000
Market Cap
$35.87 million
Optionable
Not Optionable
Beta
1.22

Key Executives

  • Dr. Peter A. Altman Ph.D. (Age 55)
    CEO, Pres & Director
    Comp: $488.06k
  • Mr. David McClung (Age 59)
    Chief Financial Officer
    Comp: $364.31k
  • Mr. Edward M. Gillis (Age 60)
    Sr. VP of Devices
    Comp: $267.79k
  • Dr. Ian McNiece Ph.D. (Age 68)
    Chief Scientific Officer
  • Dr. Sujith Shetty
    Chief Medical Officer and VP of Clinical & Regulatory













BCDA Stock - Frequently Asked Questions

Should I buy or sell BioCardia stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioCardia in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BCDA shares.
View BCDA analyst ratings
or view top-rated stocks.

What is BioCardia's stock price forecast for 2022?

2 Wall Street research analysts have issued 12-month price targets for BioCardia's stock. Their BCDA share price forecasts range from $4.00 to $9.00. On average, they anticipate the company's stock price to reach $6.50 in the next year. This suggests a possible upside of 221.8% from the stock's current price.
View analysts price targets for BCDA
or view top-rated stocks among Wall Street analysts.

How have BCDA shares performed in 2022?

BioCardia's stock was trading at $1.94 at the beginning of the year. Since then, BCDA shares have increased by 4.1% and is now trading at $2.02.
View the best growth stocks for 2022 here
.

When is BioCardia's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our BCDA earnings forecast
.

How were BioCardia's earnings last quarter?

BioCardia, Inc. (NASDAQ:BCDA) posted its earnings results on Wednesday, August, 10th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.14. The firm earned $0.97 million during the quarter, compared to analyst estimates of $0.19 million. BioCardia had a negative trailing twelve-month return on equity of 126.57% and a negative net margin of 619.91%. During the same period in the previous year, the business earned ($0.20) EPS.

When did BioCardia's stock split?

Shares of BioCardia reverse split before market open on Friday, November 3rd 2017. The 1-12 reverse split was announced on Thursday, November 2nd 2017. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 2nd 2017. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

What other stocks do shareholders of BioCardia own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioCardia investors own include Arotech (ARTX), CytoDyn (CYDY), China Gold International Resources (CGG), BioSolar (BSRC), Blink Charging (BLNK), Aurcana Silver (AUNFF), American Manganese (AMY) and

When did BioCardia IPO?

(BCDA) raised $51 million in an IPO on the week of July 20th 2015. The company issued 3,900,000 shares at a price of $12.00-$14.00 per share. Cantor Fitzgerald & Co. acted as the underwriter for the IPO and Roth Capital Partners and Maxim Group were co-managers.

What is BioCardia's stock symbol?

BioCardia trades on the NASDAQ under the ticker symbol "BCDA."

Who are BioCardia's major shareholders?

BioCardia's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Millennium Management LLC (0.16%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Eric Duckers, Jim L Allen and Peter Altman.
View institutional ownership trends
.

How do I buy shares of BioCardia?

Shares of BCDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioCardia's stock price today?

One share of BCDA stock can currently be purchased for approximately $2.02.

How much money does BioCardia make?

BioCardia (NASDAQ:BCDA) has a market capitalization of $35.87 million and generates $1.01 million in revenue each year. The company earns $-12,620,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis.

How can I contact BioCardia?

BioCardia's mailing address is 125 SHOREWAY ROAD SUITE B, SAN CARLOS CA, 94070. The official website for the company is www.biocardia.com. The company can be reached via phone at (650) 226-0120, via email at investors@biocardia.com, or via fax at 310-861-5299.

This page (NASDAQ:BCDA) was last updated on 9/28/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.